Day: March 14, 2022

Second quarter revenue of $34.0 million increased 28% sequentially and 8% year-over-year compared to FY2021 Enzo Biochem posted highest quarterly revenue in history of the Company Enzo Life Science revenue reached $10.4 million, an increase of 39% year over year Received LDT regulatory approval from New York State for CT/NG/TV molecular tests Q2 FY22 product margin increased to 49% compared to 40% in Q1 FY22 and 47% Q2 FY21 CEO advances strategy to focus on core competencies while strengthening and augmenting management teamConference call and live webcast scheduled for today,Monday, March 14, 2022 at 4:30 pm (ET) NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2022 and provided...

AUSTIN, March 14, 2022 (GLOBE NEWSWIRE) — Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, reported results for the fourth quarter and year ended December 31, 2021. “Our fourth quarter and full year results show the many benefits of our growth strategy,” said Chairman and CEO, Pat Goepel. “We continue to execute determinedly on the key priorities that we believe will drive future revenues and value creation. These priorities include a resolute focus on enhancing organic revenue growth, on executing acquisitions in our core target markets to build scale and profitability, on investments in sales and marketing to drive future revenue and on product and platform innovations that add value for our customers. Our strategy drove 29% annual growth in revenues...

Q4 2021 revenue $16.2 million and FY 2021 revenue $54.9 millionFY 2022 revenue guidance $69 – 71 million MARLBOROUGH, Mass., March 14, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2021. “Our strong finish to 2021 demonstrates the continued and accelerating adoption of our leading spatial biology solutions and is a result of sound execution of our financial and strategic plans,” said Brian McKelligon, Chief Executive Officer, Akoya Biosciences.  “We set another record in quarterly revenue, grew our installed base to nearly 700 instruments worldwide, and have approximately 500 publications on Akoya platforms to date. Highlighting our strong quarter was the commercial launch...

Expecting Saturn-2 Phase 3 topline data in April 2022, the second pivotal of TP-03 for the treatment of Demodex blepharitis, and NDA submission this year Advancing pipeline this year with planned Phase 2 initiations of TP-03 for Meibomian Gland Disease and TP-04 for Rosacea, and TP-05 Phase 1b data for Lyme disease prevention Anticipated cash runway into at least the second half of 2024, inclusive of $171 million of cash as of December 31, 2021, expected milestones from China out-license, and credit facility availability IRVINE, Calif., March 14, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December...

NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter and full year ended December 31, 2021. Fourth Quarter and Recent Business UpdatesU.S. commercial launch of PoNS® for multiple sclerosis (“MS”) progressed with first prescriptions received this month. Received marketing authorization in Australia for sale of PoNS as a Class IIa medical device to improve balance and gait. Launched partnership with Medical University of South Carolina for collaborative clinical trial on stroke, allowing for observation of PoNS therapy in a real-world clinical setting. Partnered with NYU Langone Health as the first clinical trial site for the Company-sponsored Therapeutic...

Quarterly revenue of $77.8 million, up 69% year-over-yearStrong Dollar-Based Net Retention Rate at over 152% Fiscal Fourth Quarter Highlights:Total revenue of $77.8 million GAAP operating margin of (52)%; Non-GAAP operating margin of (35)% GAAP net loss per share of $(0.32); Non-GAAP net loss per share of $(0.16)Fiscal Year 2022 Highlights:Total revenue of $252.7 million GAAP operating margin of (51)%; Non-GAAP operating margin of (39)% GAAP net loss per share of $(1.95); Non-GAAP net loss per share of $(1.20)SAN FRANCISCO, March 14, 2022 (GLOBE NEWSWIRE) — All-Remote — GitLab Inc. (NASDAQ: GTLB), The DevOps Platform, today reported financial results for its fourth quarter and full year of fiscal 2022, ended January 31, 2022. “We are seeing continued strong momentum for customers adopting our DevOps platform, as revenue...

DENVER, March 14, 2022 (GLOBE NEWSWIRE) — EverCommerce Inc. (NASDAQ: EVCM), a leading service commerce platform, today announced financial results for the quarter and year ended December 31, 2021. Fourth Quarter 2021 Financial HighlightsRevenue of $135.6 million, compared to previously issued guidance of $129.5 million to $131 million, an increase of 47% compared to $92.0 million for the quarter ended December 31, 2020. YoY Pro forma revenue growth rate of 24% and 21% for the quarter- and year ended December 31, 2021, respectively. Net loss was $82.0 million, or ($0.82) per basic and diluted share, for the year ended 2021. This compares to a net loss of $60.0 million, or ($3.06) per basic and diluted share, for the year ended 2020. Net loss was $4.7 million, or ($0.02) per basic and diluted share, for the quarter ended December 31,...

37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) — Sema4 Holdings Corp. (Nasdaq: SMFR) (“Sema4”), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and operational initiatives. “2021 was a transformative year during which we grew our test volumes and patient database, further established Sema4 as a partner...

SANTA PAULA, Calif., March 14, 2022 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global avocado-industry leader and provider of value-added fresh food, today reported its financial results for the first quarter ended January 31, 2022. First Quarter Financial OverviewTotal revenue of $274.1 million, a 24% increase from the year-ago quarter. Fresh segment revenue increased 41% year-over-year to $162.6 million, and Renaissance Food Group (RFG) and Foods segments revenues increased 6% and 4% year-over-year, respectively. Gross profit of $13.2 million, or 4.8% of revenue, compared to $17.8 million, or 8.1% of revenue, for the year-ago quarter. Net loss of $(4.0) million, or $(0.23) per diluted share, compared to net income of $5.3 million, or $0.30 per diluted share, for the same period last year. Adjusted net loss...

Quarterly Revenue Up 695% Year-Over-Year to $6.2 Million, Full Year Revenue Up 466% Year-Over-Year to $11.7 Million Surpassed 11 Billion Views in 2021; Currently Reaching 75 Million Monthly Active Players in the Gaming Metaverse SANTA MONICA, Calif., March 14, 2022 (GLOBE NEWSWIRE) — Super League Gaming (Super League or the Company) (Nasdaq: SLGG), a leading network of metaverse games, monetization tools, and content channels, reported financial results and recent operational developments for the fourth quarter and full year ended December 31, 2021. Financial Highlights and Recent Operational DevelopmentsFourth quarter 2021 revenues reached a record $6.2 million, up 695% compared to fourth quarter 2020. Full year 2021 revenues of $11.7 million, up 466% compared to full year 2020, with increases in all primary revenue streams. Advertising...